Pay in 4 interest-free payments of $7.01 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) A substudy of the phase 2 obesity trial specifically examined GLP3 s effects on liver fat in participants with metabolic dysfunction-associated steatotic liver disease[12]: Mean relative liver fat reduction of 82.4% with 12 mg dose at 24 weeks 86% of participants on 12 mg achieved normal liver fat levels (below 5%) at 24 weeks Liver fat reductions significantly correlated with improvements in insulin sensitivity, abdominal fat, and metabolic parameters Dose-dependent improvements observed across all dose groups compared to placebo These results suggest potential therapeutic applications beyond weight management, addressing hepatic complications of obesity and metabolic syndrome
From $299
H.NakagawaT.FengL.WatanabeS.HanL.MazzaliM.et al (2002)
USA 94 , 1321513220 (1997)
Assess your symptoms online for free Sign up to the Patient newsletter Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control
US$ 28.78
US$ 22.02
US$ 21.53
US$ 27.25
